Top 7 Liver Disease treatment startups in USA
Nov 19, 2025
|
Like
19
1
Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
2
Funding: $1.9B
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
3
Funding: $951.1M
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
4
Funding: $497M
Mirum Pharmaceuticals develops drugs for rare cholestatic liver diseases.
Mirum Pharmaceuticals develops drugs for rare cholestatic liver diseases.
5
Funding: $304.5M
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
6
Funding: $35M
Inipharm is building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease.
Inipharm is building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease.
7
Funding: $3M
In Diagnostics is developing next generation disposable lab-quality spectrophotometer that rely on digital microchips to analyze biological samples.
In Diagnostics is developing next generation disposable lab-quality spectrophotometer that rely on digital microchips to analyze biological samples.
★
See also:
